Search
Now showing items 1-10 of 41
Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques.
(PLoS Pathog, 2015-08)
HIV-1 mucosal transmission begins with virus or virus-infected cells moving through
mucus across mucosal epithelium to infect CD4+ T cells. Although broadly neutralizing
antibodies (bnAbs) are the type of HIV-1 antibodies ...
The Center for HIV/AIDS Vaccine Immunology (CHAVI) multi-site quality assurance program for cryopreserved human peripheral blood mononuclear cells.
(J Immunol Methods, 2014-07)
The Center for HIV/AIDS Vaccine Immunology (CHAVI) consortium was established to determine
the host and virus factors associated with HIV transmission, infection and containment
of virus replication, with the goal of advancing ...
HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria.
(Cell Host Microbe, 2014-08-13)
Monoclonal antibodies derived from blood plasma cells of acute HIV-1-infected individuals
are predominantly targeted to the HIV Env gp41 and cross-reactive with commensal bacteria.
To understand this phenomenon, we examined ...
Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing.
(PLoS Pathog, 2012)
A precise molecular identification of transmitted hepatitis C virus (HCV) genomes
could illuminate key aspects of transmission biology, immunopathogenesis and natural
history. We used single genome sequencing of 2,922 half ...
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9.
(Nature, 2011-11-23)
Variable regions 1 and 2 (V1/V2) of human immunodeficiency virus-1 (HIV-1) gp120 envelope
glycoprotein are critical for viral evasion of antibody neutralization, and are themselves
protected by extraordinary sequence diversity ...
Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated.
(J Exp Med, 2011-10-24)
The initial antibody response to HIV-1 is targeted to envelope (Env) gp41, and is
nonneutralizing and ineffective in controlling viremia. To understand the origins
and characteristics of gp41-binding antibodies produced ...
Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication.
(J Virol, 2012-06)
CD8-mediated virus inhibition can be detected in HIV-1-positive subjects who naturally
control virus replication. Characterizing the inhibitory function of CD8(+) T cells
during acute HIV-1 infection (AHI) can elucidate ...
Isolation of HIV-1-neutralizing mucosal monoclonal antibodies from human colostrum.
(PLoS One, 2012)
BACKGROUND: Generation of potent anti-HIV antibody responses in mucosal compartments
is a potential requirement of a transmission-blocking HIV vaccine. HIV-specific, functional
antibody responses are present in breast milk, ...
Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design.
(J Virol, 2012-04)
Plasma from a small subset of subjects chronically infected with HIV-1 shows remarkable
magnitude and breadth of neutralizing activity. From one of these individuals (CH0219),
we isolated two broadly neutralizing antibodies ...
HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees.
(Journal of virology, 2018-04)
Induction of broadly cross-reactive antiviral humoral responses with the capacity
to target globally diverse circulating strains is a key goal for HIV-1 immunogen design.
A major gap in the field is the identification of ...